<DOC>
	<DOCNO>NCT02793583</DOCNO>
	<brief_summary>This research study evaluate safety efficacy study drug call TGR-1202 combination another study drug call ublituximab compare TGR-1202 alone possible treatment Diffuse Large B-cell Lymphoma ( DLBCL ) come back responded standard treatment .</brief_summary>
	<brief_title>Study Assess Efficacy Safety Ublituximab + TGR-1202 TGR-1202 Alone Patients With Previously Treated Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Diagnosis Diffuse Large BCell Lymphoma Relapsed refractory prior standard therapy subject candidate highdose therapy autologous stem cell transplant Eastern Cooperative Oncology Group ( ECOG ) score 0 2 Any major surgery , chemotherapy immunotherapy within last 21 day Evidence hepatitis B virus , hepatitis C virus know HIV infection Autologous hematologic stem cell transplant within 3 month study entry . Prior Allogeneic hematologic stem cell transplant exclude Prior therapy PI3K delta inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>